Skip to content
DataLookout
Menu

NCT07904754

Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis

StatusNot Yet Recruiting
PhasePhase 2
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Study First Submitted

Endpoints

Primary

Percentage of Participants Achieving ACR50 Response
Timeframe: Week 12
Number of Participants Experiencing Adverse Events
Timeframe: Up to 80 Weeks

Secondary (7)

Percentage of Participants Achieving ACR20 Response
Percentage of Participants Achieving ACR70 Response
Percentage of Participants Achieving Low Disease Activity Based on DAS28 (CRP) <= 3.2
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) < 2.6
Percentage of Participants with a Change From Baseline in DAS28 (CRP)
Show 2 moreShow less
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) <= 10
Percentage of Participants Achieving Clinical Remission Based on CDAI <= 2.8

Arms and interventions

ABBV-2294 Dose AExperimental

Participants will receive co-administration of ABBV-722 and upadacitinib

ABBV-2294 Dose BExperimental

Participants will receive co-administration of ABBV-722 and upadacitinib

ABBV-2294 Dose CExperimental

Participants will receive co-administration of ABBV-722 and upadacitinib

ABBV-722 MonotherapyExperimental

Participants will receive ABBV-722. At Week 12, participants will then be blindly switched to co-administration of ABBV-722 and upadacitinib.

Upadacitinib MonotherapyActive comparator

Participants will receive upadacitinib.

Drugs: ABBV-722, Upadacitinib